Vedroprevir

Star0

DB12037InvestigationalSmall molecule

Vedroprevir has been investigated for the treatment of Hepatitis C, Chronic.

Formula / weight: C₄₅H₆₀ClN₇O₉S · 910.53 g/mol (avg)
Code names: GS-9451

Resolves to

Compound

UNIIKGD958X2B9CAS1098189-15-1ChEMBLCHEMBL2013174PubChem25167947

Structure

InChIKeyOTXAMWFYPMNDME-FQQWJMKMSA-NSMILES

CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@@H]2C[C@@H]2C1)C(C)(C)C)OC1=C2C=CC(OCCN3CCOCC3)=C(Cl)C2=NC(=C1)C1=CSC(NC(C)C)=N1)C(O)=O

Targets

P26664Genome polyprotein

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Vedroprevir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account